Tolvaptan

🧮 Dose calculator

Hyponatraemia · Regimen source: FDA Samsca · 2.1

• • Start only in hospital; over-rapid correction causes osmotic demyelination. Increase to 30 then up to 60 mg at ≥24-h intervals. FDA Samsca · 2.1FDA Samsca · Boxed Warning

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Samsca · 8.1

  “Risk Summary Available data with SAMSCA use in pregnant women are insufficient to determine if there is a drug-associated risk of adverse developmental outcomes.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Samsca · 8.2

  “Because of the potential for serious adverse reactions, including electrolyte abnormalities (e.g., hypernatremia), hypotension, and volume depletion in breastfed infants, advise women not to breastfeed during treatment with SAMSCA.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Samsca · 8.4

  “Safety and effectiveness of SAMSCA in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Samsca · 8.5

  “Of the total number of hyponatremic subjects treated with SAMSCA in clinical studies, 42% were 65 years old and over, while 19% were 75 years old and over.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.